APA (7th ed.) Citation

E, D., R, K., SA, R., T, T., CFS, J., & M, F. (2024). Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's Disease: A retrospective cohort study. International journal of impotence research, 36(2), 151. https://doi.org/10.1038/s41443-023-00810-5

Chicago Style (17th ed.) Citation

E, Durukan, Kraglund R, Rashid SA, Thorkilgaard T, Jensen CFS, and Fode M. "Phosphodiesterase Type 5 Inhibitors Do Not Prevent Curvature Progression but Shorten Pain Duration in the Active Phase of Peyronie's Disease: A Retrospective Cohort Study." International Journal of Impotence Research 36, no. 2 (2024): 151. https://doi.org/10.1038/s41443-023-00810-5.

MLA (9th ed.) Citation

E, Durukan, et al. "Phosphodiesterase Type 5 Inhibitors Do Not Prevent Curvature Progression but Shorten Pain Duration in the Active Phase of Peyronie's Disease: A Retrospective Cohort Study." International Journal of Impotence Research, vol. 36, no. 2, 2024, p. 151, https://doi.org/10.1038/s41443-023-00810-5.